Media Centre
In The News
In The News
This site uses session cookies only. These enable core functionality and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.
ContinueWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy
Engitix Therapeutics: beyond the cells
Biopharma Dealmakers – Nature – View full story
Fighting fibrosis
Nature Biotechnology – View full story
Anti-Inflammatory Drugs Demonstrate Pathway Savvy
Genetic Engineering & Biotechnology News – View full story
Engitix expands collaboration with Takeda to include therapeutics for fibrostenotic IBD
BioWorld – View full story (behind a paywall)
Backed by billionaire Mike Platt, Engitix scores another deal with Takeda to go after IBD
Endpoints – View full story
Engitix and Takeda extend partnership for anti-fibrotic therapy development
Pharmaceutical Technology – View full story
With $300M up for grabs, Engitix helps Takeda dig into extracellular matrix in search of IBD drugs
Fierce Biotech – View full story
Billionaire Platt-Backed Engitix Inks $300 Million Takeda Deal
Bloomberg – View full story
The Top European Biotech Investments in January 2022
Labiotech – View full story
Engitix raises $54 million to advance ECM target discovery platform
BioWorld – View full story (behind a paywall)
Engitix collaborates with Dompé on fibrosis and cancer as it eyes the clinic
SCRIP – View full story (behind a paywall)
Engitix builds liver disease pipeline with series A and drug collaboration
Labiotech.eu – View full story
Dompé signs strategic collaboration with Engitix and joins Series A for Engitix
LaingBuisson – View full story
Engitix and Dompé collaboration for fibrosis and cancer AI drug discovery
Pharmafile – View full story
Billionaire Platt-backed biotech startup raises $54 million
Bloomberg – View full story
British billionaire Mike Platt hops on board a London startup looking at drug discovery from a different angle
Endpoints News – View full story
Takeda bets on Engitix’s ECM drug discovery platform for liver fibrosis
Pharmaceutical Technology – View full story
Takeda, Engitix ink $500 million deal for liver fibrosis therapy
BioWorld – View full story (behind a paywall)
Takeda inks up to $500 million collaboration with extra-cellular matrix biotech for NASH
Endpoints News – View full story
Asia Deal Watch: Takeda Will Employ Engitix’s ECM Tech In Liver Fibrosis Indications
SCRIP – View full story (behind a paywall)
Engitix Receives a Golden Ticket to LabCentral from Takeda to Advance Fibrosis and Solid Tumour Research
Bloomberg – View full story